MedTrace Logo

Metabolic Modulation as Treatment in Acute Heart Failure

NCT00449423 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2007-10-25

No results posted yet for this study

Summary

The primary objective of this study is to evaluate whether metabolic modulation improves hemodynamics and outcome in acute heart failure

Conditions

  • Acute Heart Failure

Interventions

DRUG

acipimox

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Mads Halbirk, dr. · Aarhus University Hospital, Department of Cardiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Completion
2007-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00449423 on ClinicalTrials.gov